An observational study on safety profile of ofloxacin and levofloxacin in treatment of acute exacerbation of chronic bronchitis

Abstract

Background COPD is predicted to be the third most common cause of death and chronic disability in the world by 2020. The term COPD encompasses several conditions. These include airflow obstruction with little reversibility, chronic bronchitis, emphysema, and small airways disease. Outcomes when hospitalized are poor, with 34% being re-admitted and 14% dying within 3 months. Aims and objectives To monitor, evaluate and compare the adverse effect profile of Ofloxacin and Ciprofloxacin in acute exacerbation of chronic bronchitis. Methods This was a prospective, observational study done in 200 patients of clinically diagnosed acute bronchitis in the department of pulmonology, SMC/GGH, Vijayawada. Newly diagnosed 200patients of acute bronchitis (from January 2017 to June 2017), pulmonology outpatient department, GGH, SMC, VJA of age 18–65 years of either gender who were prescribed either Levofloxacin (n = 100) or ofloxacin (OZP group, n = 100) and who gave written informed consent were enrolled. One group of the patients received Tab. Ofloxacin 400 mg BD and other group received Tab. Levofloxacin 500 mg OD for 7 days. The study duration was 6 months. Results In Ofloxacin group 63 patients reported ADRs out of which 40 are male and 23 are female. In Levofloxacin group, 19 patients reported ADR, of which 10 were men and 09 women (figure 1). Out of 63 ADRs in ofloxacin group 50 patients reported ADRs associated with CNS, 11patients reported ADRs associated with GIT & 02were associated with skin and its appendages. Out of 19 ADRs in levofloxacin group 10 patients reported ADRs associated with CNS, 08 patients reported ADRs associated with GIT & 01were associated with skin and its appendages (figure 2). Conclusion Even though, fluoroquinolones have excellent efficacy profile there are concerns about their safety. The present study concluded that no serious ADRs noted in both groups. But ofloxacin group of patients have shown increased incidence of ADRs associated with CNS especially Insomnia.

Authors and Affiliations

K Sankar

Keywords

Related Articles

Hypoglycemic effect of ethanolic extract of hedychium coronarium linn. rhizome in alloxan induced diabetes in rat model

Purpose To study the hypoglycemic effect of ethanolic extract of Hedychium coronarium Linn. rhizome in alloxan induced diabetes in rat model. Methods The preliminary photochemical studies were carried out on the crude e...

Analysis of the current trend in the prescription of anti-hypertensive drugs among pregnant females in a tertiary care hospital

Background Hypertensive disorders are the leading cause of maternal and perinatal mortality and morbidity in India and worldwide, as it is among the most common of all medical complications in pregnancy. Material & Meth...

Formulation and Characterization of Aspirin loaded modified release Microsponges by statistical design

Aspirin loaded microsponge can be used to deliver particles to the intestinal region for reducing the side effects and give sustained release effect. Quasi emulsion solvent diffusion method was used to prepare Aspirin lo...

Cervical lymph Node Enlargement

Cervical lymph nodes are enlarged in almost all neck and head pathologies. Tuberculosis was the major cause for cervical lymphadenopathy. Pathological examination was also mandatory. Lymph node enlargement is seen in a...

Review on non -pharmacological treatment for type-2 diabetes mellitus

This study reviewed the research reports dealing with non- pharmacologic interventions aimed at preventing type 2 diabetes including diet and physical activity, for the prevention of Type-2DM.Lifestyle interventions red...

Download PDF file
  • EP ID EP648128
  • DOI -
  • Views 66
  • Downloads 0

How To Cite

K Sankar (2019). An observational study on safety profile of ofloxacin and levofloxacin in treatment of acute exacerbation of chronic bronchitis. International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP), 8(2), 131-136. https://europub.co.uk/articles/-A-648128